Is It Too Late To Consider Penumbra (PEN) After Strong 1 Year Share Price Gains?

• If you are wondering whether Penumbra's current share price lines up with its underlying worth, you are not alone. This article is aimed squarely at that question.
• The stock last closed at US$334.99, with returns of 8.3% year to date and 28.5% over the past year, although the past week and month showed 1.7% and 1.2% declines respectively.
• Recent coverage around Penumbra has focused on its position in the medical devices space and how investors see its long term growth story. This helps frame the share price moves you are seeing now. This mix of enthusiasm and caution in the news flow is useful context before putting any numbers into a valuation model.
• Right now, Penumbra has a valuation score of 0 out of 6. We will look at what different valuation approaches say about that result and finish by considering a broader way to think about value beyond a single score.

Penumbra scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Penumbra Discounted Cash Flow (DCF) Analysis

A DCF model takes estimates of the cash a company could generate in the future, then discounts those cash flows back to today to arrive at an estimate of what the business might be worth now.

For Penumbra, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in US$. The latest twelve month free cash flow is about US$199.9 million. Analysts have provided forecasts up to 2027, with free cash flow of US$255.6 million in that year. Beyond that point, Simply Wall St extrapolates further, with the 2035 projection at US$442.6 million. All figures are still below US$1b so are best thought of in millions.

Pulling these projections together, the model arrives at an estimated intrinsic value of US$183.86 per share. Against the recent share price of US$334.99, this implies the stock is 82.2% overvalued on this DCF view.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Penumbra may be overvalued by 82.2%. Discover 47 high quality undervalued stocks or create your own screener to find better value opportunities.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Penumbra.

Approach 2: Penumbra Price vs Earnings

For profitable companies, the P/E ratio is a useful way to check how much you are paying for each dollar of earnings. It links directly to what the business is currently earning, which many investors find easier to relate to than a full cash flow model.

What counts as a "normal" P/E depends on what the market expects from a company and how risky those earnings appear. Higher expected growth and lower perceived risk can support a higher P/E, while lower growth or higher uncertainty usually call for a lower one.

Penumbra is trading on a P/E of 73.98x, compared with the Medical Equipment industry average of 26.87x and a peer group average of 36.27x. Simply Wall St also calculates a proprietary Fair Ratio of 29.46x. This Fair Ratio is designed to be more tailored than a simple peer or industry comparison because it incorporates factors such as earnings growth expectations, profit margins, market capitalization, risks and the company’s industry.

Set against this Fair Ratio of 29.46x, Penumbra’s current P/E of 73.98x suggests the shares are trading at a higher multiple than would typically be expected on these characteristics.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Penumbra Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. These are simply your story about Penumbra linked directly to your own assumptions for future revenue, earnings, margins and fair value, then compared with the current price to help you decide whether you see it as attractive or not.

On Simply Wall St’s Community page, Narratives are a straightforward tool used by millions of investors. You set your expectations, the platform turns those into a financial forecast and fair value, and then keeps that view updated when new information such as earnings releases or news about events like the proposed Boston Scientific acquisition or the STORM-PE trial comes through.

For Penumbra, one investor might build a Narrative closer to the higher analyst fair value of about US$360.13 or the bullish US$355.00 target based on stronger revenue growth and margins. Another might lean toward the lower US$238.98 bearish view. By comparing each Narrative’s fair value to today’s share price, they can decide whether the stock looks too expensive, too cheap or roughly in line with their expectations.

For Penumbra however we will make it really easy for you with previews of two leading Penumbra Narratives:

🐂 Penumbra Bull Case

Fair value: US$360.13

Implied discount to this fair value: 7.0% below it based on the recent US$334.99 share price

Revenue growth assumption: 13.22% a year

• Leans on the STORM PE trial, new thrombectomy and embolization products, and global rollout of platforms such as Flash 2.0 and Bolt to support higher procedure volumes and margins.
• Assumes steady expansion in international markets and ongoing investment in clinical data to support pricing, reimbursement and earnings strength over time.
• Ties these assumptions to a fair value of about US$360 per share, with analysts on average viewing the current price as close to that level and encouraging you to test their numbers against your own view.

🐻 Penumbra Bear Case

Fair value: US$238.98

Implied premium to this fair value: 40.1% above it based on the recent US$334.99 share price

Revenue growth assumption: 13.19% a year

• Focuses on the risk that procedure growth in VTE and PE might not match expectations if hospital protocols, budgets or reimbursement slow adoption.
• Highlights competition in thrombectomy and embolization, the cost of a larger sales force and uncertainty around next generation platforms as possible limits on margins and earnings.
• Builds these views into a lower fair value of about US$239 per share, implying analysts in this camp see current market expectations as high and encouraging you to weigh whether their growth and margin assumptions feel reasonable.

Both Narratives use the same company but very different assumptions about how product adoption, margins and valuation multiples might play out. Reading them side by side can help you decide which story feels closer to your own expectations before you make any moves on the stock.

Do you think there's more to the story for Penumbra? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com